dual anti-CD19/anti-CD20 CAR T-cell therapy (Intas Pharmaceuticals)

N/A

Report date: 2025/03/19 08:58:26

Base Information

Drug Namedual anti-CD19/anti-CD20 CAR T-cell therapy (Intas Pharmaceuticals)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIntas Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesIntas Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A